Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for retatrutide in TRANSCEND-T2D-1 on March 19, 2026. At 40 weeks, retatrutide produced up to 2.0% A1C reduction and up to 16.8% weight loss (36.6 lbs) versus placebo, meeting primary and all key secondary endpoints.
Improvements were seen across doses (4 mg, 9 mg, 12 mg) and cardiovascular risk markers; common adverse events were nausea, diarrhea and vomiting, mostly during dose escalation.
Lilly (NYSE: LLY) reported positive topline Phase 3 ADorable-1 results for EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis on March 16, 2026. At Week 16, EBGLYSS achieved EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 improvement 35%. Safety was consistent with adult/adolescent studies, with no new signals and no injection site pain reported. Lilly plans regulatory submissions for potential pediatric label updates; the ADorable program and a 52-week extension continue.
Eli Lilly (NYSE: LLY) launched the Lilly Employer Connect platform on March 5, 2026 to expand employer-sponsored access to obesity medicines. The program starts with over 15 independent program administrators and offers Zepbound KwikPen at a discounted price of $449 per device across all doses to participating network pharmacies.
The platform enables flexible cost-share models and nationwide pharmacy support, while preserving provider and patient choice. Clinical data cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks vs 3.1% placebo) and SURMOUNT-5 open-label comparisons.
Eli Lilly (NYSE: LLY) announced a positive CHMP opinion recommending Olumiant (baricitinib) for adolescents ages 12 to <18 with severe alopecia areata. The recommendation is based on Phase 3 BRAVE-AA-PEDS results showing 42.4% achieved ≥80% scalp hair coverage at 36 weeks (4 mg).
The opinion moves to the European Commission for final action, expected in one to two months; a U.S. decision is expected in the second half of 2026.
Chondrosarcoma market (covering 7MM) is forecast to grow from 2026–2036 as diagnosis improves and new therapies advance. Approximately 1,400 incident US cases were reported in 2024–25. Emerging drugs include Ozekibart (INBRX-109), TIBSOVO (ivosidenib), and LY3410738 (LLY), with planned regulatory filings and ongoing pivotal trials.
The pipeline remains limited; however, Fast Track designations, positive Phase II topline data, a planned BLA in Q2 2026, and a Phase III primary completion expected Feb 2028 could reshape care for unresectable and metastatic disease.
Eli Lilly (NYSE: LLY) reported 52-week ACHIEVE-3 results showing oral orforglipron outperformed oral semaglutide on A1C and weight. At 36 mg, orforglipron reduced A1C by 2.2% vs 1.4% and produced 9.2% weight loss (19.7 lbs) vs 5.3% (11.0 lbs).
Orforglipron improved multiple cardiovascular risk factors, had higher treatment discontinuation rates, and has regulatory submissions in >40 countries with potential U.S. obesity action in Q2 2026.
Eli Lilly (NYSE: LLY) announced FDA approval of a four-dose, single-patient Zepbound KwikPen that delivers a month of treatment in one device. The KwikPen joins single-dose vials and is available by prescription with LillyDirect self-pay pricing starting at $299/month for 2.5 mg. Clinical highlights cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks) and SURMOUNT-5 (average 50 lb loss vs 33 lb with comparator).
The release reiterates safety warnings, dosing options (2.5–15 mg) and contraindications for MTC and MEN 2.
Eli Lilly (NYSE: LLY) reported long-term VIVID program results showing durable Crohn's disease control with Omvoh (mirikizumab-mrkz): among patients who achieved outcomes at Year 1, clinical remission 92.4%, corticosteroid-free remission 91.2% at Week 152, and sustained bowel urgency improvements.
Post hoc analyses showed nearly 50% fewer Crohn's-related hospitalizations/surgeries weeks 0–12 and nearly 70% fewer during weeks 12–52 versus placebo; Omvoh is approved in 47 countries.
Eli Lilly (NYSE: LLY) reported positive topline 36-week results from the Phase 3b TOGETHER-PsO trial: concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) met the primary endpoint and all key secondaries versus Taltz alone.
Key results: 27.1% reached PASI 100 plus ≥10% weight loss vs 5.8% (p<0.001); 40.6% achieved PASI 100 vs 29.0% (p<0.05). Mean BMI >39 kg/m2. Adverse events were generally mild to moderate and consistent with known profiles. Detailed 36-week data will be published and discussed with regulators.
Scribe Therapeutics announced a second success milestone in its in vivo CRISPR collaboration with Eli Lilly (NYSE: LLY), advancing a target for neurological and neuromuscular diseases. The achievement further validates Scribe’s X-Editor (XE) platform and CRISPR by Design engineering approach.
Under the 2023 agreement, Scribe is eligible for more than $1.5 billion in potential milestone payments across programs plus low-double-digit royalties, and the companies previously reported an initial milestone and a 2025 ASGCT presentation.